» Articles » PMID: 34082800

Birth Prevalence of Phenylalanine Hydroxylase Deficiency: a Systematic Literature Review and Meta-analysis

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2021 Jun 4
PMID 34082800
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Phenylalanine hydroxylase (PAH) deficiency is an autosomal recessive disorder that results in elevated concentrations of phenylalanine (Phe) in the blood. If left untreated, the accumulation of Phe can result in profound neurocognitive disability. The objective of this systematic literature review and meta-analysis was to estimate the global birth prevalence of PAH deficiency from newborn screening studies and to estimate regional differences, overall and for various clinically relevant Phe cutoff values used in confirmatory testing.

Methods: The protocol for this literature review was registered with PROSPERO (International prospective register of systematic reviews). Pubmed and Embase database searches were used to identify studies that reported the birth prevalence of PAH deficiency. Only studies including numeric birth prevalence reports of confirmed PAH deficiency were included.

Results: From the 85 publications included in the review, 238 birth prevalence estimates were extracted. After excluding prevalence estimates that did not meet quality assessment criteria or because of temporal and regional overlap, estimates from 45 publications were included in the meta-analysis. The global birth prevalence of PAH deficiency, estimated by weighting regional birth prevalences relative to their share of the population of all regions included in the study, was 0.64 (95% confidence interval [CI] 0.53-0.75) per 10,000 births and ranged from 0.03 (95% CI 0.02-0.05) per 10,000 births in Southeast Asia to 1.18 (95% CI 0.64-1.87) per 10,000 births in the Middle East/North Africa. Regionally weighted global birth prevalences per 10,000 births by confirmatory test Phe cutoff values were 0.96 (95% CI 0.50-1.42) for the Phe cutoff value of 360 ± 100 µmol/L; 0.50 (95% CI 0.37-0.64) for the Phe cutoff value of 600 ± 100 µmol/L; and 0.30 (95% CI 0.20-0.40) for the Phe cutoff value of 1200 ± 200 µmol/L.

Conclusions: Substantial regional variation in the birth prevalence of PAH deficiency was observed in this systematic literature review and meta-analysis of published evidence from newborn screening. The precision of the prevalence estimates is limited by relatively small sample sizes, despite widespread and longstanding newborn screening in much of the world.

Citing Articles

[ expression and functional analyses of the mutants p.R243Q, p.R241C and p.Y356X of the human phenylalanine hydroxylase].

Pang Y, Gao X, Yuan Z, Huang H, Wang Z, Peng L Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(2):188-193.

PMID: 38436318 PMC: 10921879. DOI: 10.7499/j.issn.1008-8830.2309035.


Recent Advances in Phenylketonuria: A Review.

Zuniga Vinueza A Cureus. 2023; 15(6):e40459.

PMID: 37456395 PMC: 10349532. DOI: 10.7759/cureus.40459.


Precision information extraction for rare disease epidemiology at scale.

Kariampuzha W, Alyea G, Qu S, Sanjak J, Mathe E, Sid E J Transl Med. 2023; 21(1):157.

PMID: 36855134 PMC: 9972634. DOI: 10.1186/s12967-023-04011-y.


Racial and ethnic diversity of classic and clinical variant galactosemia in the United States.

Stettner N, Cutler D, Fridovich-Keil J Mol Genet Metab. 2023; 138(4):107542.

PMID: 36848716 PMC: 10133179. DOI: 10.1016/j.ymgme.2023.107542.


Genetic evaluation of hyperphenylalaninemia patients with tetrahydrobiopterin deficiency in Iranian population: Identification of four novel disease-causing variants.

Sadat Fatemi S, Eshraghi P, Ghanei M, Hamzehloei T Mol Genet Genomic Med. 2022; 10(12):e2081.

PMID: 36382472 PMC: 9747554. DOI: 10.1002/mgg3.2081.


References
1.
Williams R, Mamotte C, Burnett J . Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochem Rev. 2008; 29(1):31-41. PMC: 2423317. View

2.
Zytkovicz T, Fitzgerald E, Marsden D, Larson C, Shih V, Johnson D . Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 2001; 47(11):1945-55. View

3.
Yoon H, Lee K, Kang S, Lee D, Yoo H, Min W . Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea: a three-year report. Clin Chim Acta. 2005; 354(1-2):167-80. DOI: 10.1016/j.cccn.2004.11.032. View

4.
Botler J, Camacho L, Cruz M . Phenylketonuria, congenital hypothyroidism and haemoglobinopathies: public health issues for a Brazilian newborn screening program. Cad Saude Publica. 2012; 28(9):1623-31. DOI: 10.1590/s0102-311x2012000900002. View

5.
Kocova M, Anastasovska V . Phenylketonuria screening in the Republic of Macedonia. Orphanet J Rare Dis. 2016; 11(1):112. PMC: 4975894. DOI: 10.1186/s13023-016-0483-2. View